Welcome to our dedicated page for OPTIMI HEALTH news (Ticker: OPTHF), a resource for investors and traders seeking the latest updates and insights on OPTIMI HEALTH stock.
Optimi Health Corp. (OPTHF) is a leading Health Canada-licensed psychedelics pharmaceutical manufacturer, specializing in controlled substances such as botanical psilocybin and MDMA. The company recently obtained a Drug Establishment Licence (DEL) from Health Canada, confirming compliance with Good Manufacturing Practices (GMP). This allows Optimi to supply MDMA and psilocybin capsules to patients with PTSD and Treatment-Resistant Depression under Australia's Authorized Prescriber Scheme and export to regulated jurisdictions globally. Optimi aims to be the trusted global supplier of safe drug candidates by producing proprietary formulations in its 20,000 square feet facilities in Princeton, BC.
Rhea-AI Summary
Optimi Health Corp. (OPTI) has successfully harvested eight new natural Psilocybin genetics, solidifying its position as a leading psychedelic research and formulation company. The company is advancing its full spectrum, GMP extract quality program and has confirmed the product's potency and quality attributes for the duration of clinical trials. Optimi is also making GMP Psilocybin API available for encapsulation into standardized dosages or sale to other groups, expanding its reach and impact within the psychedelic research community.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
11.74%
Tags
-
Rhea-AI Summary
Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FRA: 8BN) announces the successful resolution of a dispute related to a supply agreement, emphasizing commitment to positive relationships and business integrity in the psychedelics sector.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Summary
Optimi Health Corp. appoints Dr. Preston A. Chase as Chief Science Officer, bringing extensive experience in R&D and commercialization of innovative products. Dr. Chase will lead the scientific team to advance research capabilities and develop safe, effective psychedelics drug candidates.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.58%
Tags
Rhea-AI Summary
Optimi Health Corp. has secured a non-dilutive Debt Financing Agreement and General Security Agreement for CAD$1,000,000. The loan is secured against the company's assets and will bear interest at a rate of 7.5% per annum. The loan is repayable on April 30, 2025, and the company has the option to repay it earlier with a prepayment fee. As part of the agreement, the company has granted 100,000 common share purchase warrants.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Summary
Optimi Health Corp. sees positive outcomes from the MAPS Phase 3 MDMA-Assisted Therapy Clinical Trial for PTSD treatment
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.54%
Tags
-
Rhea-AI Summary
Optimi Health Corp. receives approval from Health Canada to supply Canada's Special Access Program with psychedelic substances.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.43%
Tags
Rhea-AI Summary
Optimi Health Corp. secures CAD$1,000,000 non-dilutive Debt Financing Agreement
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.14%
Tags
-
Rhea-AI Summary
Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FRA: 8BN) secures CAD $1,000,000 from Catcher Investments Ltd. for a non-dilutive Debt Financing Agreement and General Security Agreement. The financing will bear interest at 7.5% per annum and mature on August 4, 2026. The company also granted 100,000 common share purchase warrants to Mr. JJ Wilson, its director and non-executive Chair.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.23%
Tags
-
News
Rhea-AI Summary
Optimi Health Corp. has successfully completed its proprietary natural psilocybin extraction process under GMP. The process increases potency while maintaining the mushroom's botanical characteristics, reducing production costs and opening new possibilities. Optimi is the only publicly listed Canadian manufacturer focused on GMP-grade psychedelics. The company has filed a U.S. provisional patent application to protect its extraction process.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.1%
Tags
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-9.03%
Tags
FAQ
What is the current stock price of OPTIMI HEALTH (OPTHF)?
The current stock price of OPTIMI HEALTH (OPTHF) is $0.152 as of December 24, 2024.
What is the market cap of OPTIMI HEALTH (OPTHF)?
The market cap of OPTIMI HEALTH (OPTHF) is approximately 14.6M.
What is Optimi Health Corp. specialized in?
Optimi is a Health Canada-licensed psychedelics pharmaceutical manufacturer, specializing in controlled substances like botanical psilocybin and MDMA.
What recent milestone did Optimi achieve?
Optimi obtained a Drug Establishment Licence (DEL) from Health Canada, affirming its compliance with Good Manufacturing Practices (GMP) to supply MDMA and psilocybin capsules for patients.
What is Optimi's goal in the pharmaceutical industry?
Optimi aims to be the top trusted supplier of safe drug candidates globally by producing proprietary formulations in its 20,000 square feet facilities in Princeton, BC.
Where is Optimi's manufacturing facility located?
Optimi's manufacturing facilities totaling 20,000 square feet are located in Princeton, British Columbia.
What licenses does Optimi hold?
Optimi holds a Controlled Drugs and Substances Dealer's Licence and a Drug Establishment Licence (DEL), enabling the production of GMP-grade products and APIs.
How does Optimi plan to support global psychedelic research?
Optimi has completed its first international shipment of MDMA to Israel, supporting global research and innovation in the psychedelic field.
What is Optimi's key achievement in terms of export?
Optimi received the necessary Export Permit from Health Canada, confirming its ability to export controlled substances internationally.
What services does Oak Hill Financial Inc. provide to Optimi?
Oak Hill Financial Inc. provides comprehensive investor relations, business, and capital markets advisory services to Optimi at a rate of CDN$12,000 per month.
How does Optimi plan to expand its shareholder base?
Optimi aims to engage new investors and communicate its corporate milestones effectively through partnerships like Oak Hill Financial Inc.
What makes Optimi unique in the pharmaceutical industry?
Optimi's unique capabilities lie in producing scalable psychedelic formulations for transformational human experiences while meeting the highest quality and safety standards.
OPTIMI HEALTH CORP
OTC:OPTHF
OPTHF Rankings
OPTHF Stock Data
14.58M
58.12M
16.52%
0.05%
Drug Manufacturers - Specialty & Generic
Healthcare
United States of America
Garibaldi Highlands